| Expression System | CHO |
|---|
| Protein Tag | C-Fc |
|---|
| Purity | > 95% by SDS-PAGE under reducing conditions |
|---|
| Endotoxin | Not tested |
|---|
| Activity | Positive |
|---|
| Conjugate | PE |
|---|
| Species | Human |
|---|
| Accession Number | P15391 |
|---|
| Protein Sequence | Glu21-Lys291 |
|---|
| Molecular Weight | The protein has a predicted molecular weight of 56kDa and migrates at approximately 70-80kDa on SDS-PAGE with DTT-reduced condition before PE conjugation. |
|---|
| Formulation | PBS buffer, pH7.4, 0.09% NaN3 with a carrier protein |
|---|
| Concentration | 25µg size is bottled at 0.1mg/mL concentration. 100 µg and 500 µg size is bottled at lot specific concentration. |
|---|
| Purification | Affinity Protein A |
|---|
| Applications | FACS |
|---|
| Format | Liquid |
|---|
| Reconstitution | NA |
|---|
| Shipping Condition | Cold Pack |
|---|
| Storage/Shelf Life | Unopened vial can be stored at 4°C for six months. |
|---|
| Background Information | CD19 is a single-pass type I membrane protein containing 2 Ig-like C2-type (immunoglobulin-like) domains. CD19 is expressed on follicular dendritic cells and B cells. In fact, it is present on B cells from earliest recognizable B-lineage cells during development to B-cell blasts but is lost on maturation to plasma cells. CD19 primarily acts as a B cell co-receptor in conjunction with CD21 and CD81. Upon activation, the cytoplasmic tail of CD19 becomes phosphorylated, which leads to binding by Src-family kinases and recruitment of PI-3 kinase. CD19 Assembles with the antigen receptor of B lymphocytes in order to decrease the threshold for antigen receptor-dependent stimulation. Defects in CD19 are the cause of immunodeficiency common variable type 3 (CVID3) which is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen. |
|---|